The recent FDA approval of darolutamide (Nubeqa) plus docetaxel and androgen deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC) represents a promising improvement in survival without a significant increase in toxicity vs ADT and chemotherapy alone for patients with advanced disease, according to E. David Crawford, MD.1
The triplet combination was approved based on results from the phase 3 ARASENS trial (NCT02799602).2 The treatment combination was found to have a statistically significant and meaningful improvement in overall survival (OS) among those treated with darolutamide plus docetaxel vs chemotherapy (HR, 0.68; 95% CI, 0.57-0.80; P <.0001). Median OS was not reached in the darolutamide arm at a median follow-up of 43.7 months and was 48.9 months in the chemotherapy arm. Patients also had a delay in time to pain progression in the darolutamide arm vs the chemotherapy arm (HR, 0.79; 95% CI, 0.66-0.95; 1-sided P = .006).
Now weve got a triplet [regimen for mHSPC], so Im excited. I was seeing patients live 10 years or longer with doublets. Now, I expect that its going to get even better. I have some patients with advanced prostate cancer alive at 20 years. What we have here is a major step forward; we have a drug that is added onto ADT and chemotherapy that had an impact. Thats something that I think is a game changer, said Crawford.
CancerNetworkspoke with Crawford, editor-in-chief of Grand Rounds in Urology; professor of Urology at the University of California, San Diego; and an editorial board member of the journal ONCOLOGY about the approval and the body of research that led to the regulatory decision. Additionally, he highlighted how the new treatment option will impact patients with mCRPC and where future efforts need to be focused to help move the needle forward.
Crawford: It represents a significant step forward in our progress of trying to effectively treat this disease and maybe even get to the point where we make it a chronic disease. Like many of the other [cancer types] out there, people don't die from it; they die with it. [The approval of darolutamide plus docetaxel and ADT] fits very nicely with the evolution of whats happened in metastatic prostate cancer. [Treatment for prostate cancer] started out with single therapy back in the 1940s with estrogens and orchiectomy. One of the big changing points was the introduction of LHRH [luteinizing hormone-releasing hormone] agonist back in the mid-1980s.
We had an effective therapy that [patients] usually progressed on within a period of a couple of years. That led to a study that [I was involved in] with a doublet therapy and an anti-androgen agent called flutamide which was published in 1989 in the New England Journal of Medicine; that was the first doublet that was utilized extensively.3 It resulted in a 6-month improvement in survival rate. At that time, it was met with a lot of controversy and for the next decade, there were a lot of studies done with it and with other doublets. Then what happened with metastatic disease was that a new generation of drugs came along. We call them third-generation anti-androgens inhibitors, androgen biosynthesis inhibitors, and chemotherapy. What happened there was we were blessed with a bunch of riches [about] a decade ago with all these new drugs like chemotherapy, which were utilized in this study [along with other treatments like] docetaxel, androgen biosynthesis inhibitors, [and abiraterone acetate].
Then we had drugs that were much better than the one I studied in 1989. We had darolutamide that came along, as well as apalutamide [Erleada] and enzalutamide [Xtandi]. When these agents were added to standard [ADT], there was an improvement in outcomes, and that reflected what we had done years ago. In 2018 or 2019, [findings read out using] doublets. If you look at the utilization and studies that have been done going back to 2020, only about a quarter of clinicians add something like this onto ADTa doublet. Were starting to see that change a little bit by moving the needle here with therapeutic interventions and change, but development in prostate cancer [like many other cancers] has been slow.
The important thing is now we have a triplet that has been well studied, where you build on the foundation of ADT including a study that was done a number of years ago by Christopher J. Sweeney, MMBS, and the [Prostate Cancer Foundation] Cooperative Group. That was called the [phase 3] CHAARTER trial [NCT00309985].4 It showed when you add docetaxel to ADT, you had improvements in outcomes of almost 17 months, which is a long time compared with the study that we did back in 1989 when the survival rates were 28 months to 35 months of improvement.
Building on that was tough, and this was a risky trial to do in a way. The ARASENS trial built on the doublet of ADT and chemotherapy and then added darolutamide, which is a third-generation anti-androgen inhibitor. What happened here was an amazing almost 35% improvement in the survival rate, just by adding [darolutamide]. Then the question was, Okay, did we add a lot of toxicity? The answer was nothere was no added toxicity on top of chemotherapy with ADT. Theres no question that chemotherapy with ADT takes its toll on [patients] more than ADT alone, which has a significant [adverse] effect profile. The ones we worry about now are more cardiovascular and bone [related].
We always like to have a personalized medicine approach, focusing on a [single patient] rather than a large group. Weve got some of that information here, but I wouldnt jump to say that [you should] take the worst patients and treat them with this regimen. Thats what the bucket of chemotherapy fell into where the benefit seemed to be working with more advanced disease. Some of that had to do with people with lesser disease who lived longer in these trials, but we did not follow patients long enough to see that. That was sort of the same with the ARASENS trial in a way; when the end point of survival difference was reached and survival in the control arm passed 50%, the study was basically stopped and people weren't followed anymore. Therefore, we may never know the right answer for some of the [included] groups.
We do know, however, that theres an improvement in survival, delay in chemotherapy, and a delay in pain. We also know that the majority of toxicity during the initial therapy with the chemotherapy and that the addition of darolutamide didnt significantly change that. How do we decide who to use it on? Many people dont agree with me, but I think it applies across the board with advanced prostate cancer. We all know that cancer that is a collection of genetic changes; the longer its around them, the more genetic heterogeneity exists and less responsive it is to that therapy. When screening, were finding the disease early. In our study from 1989, we found that people with more minimal disease did lived longer, and it wasnt just lead time bias. Hitting this [disease] heavy up front as you do with a lot of [curable] cancers makes sense, and right now, its open to most patients, not just those who have more significant disease.
History remakes itself all the time in prostate cancer, and what we found out was that it used to be that drugs were studied with advanced disease, including hormone therapy and some of the anti-androgens. What happened was we were treating [patients] and then [treatment] would fail. Theyd have advanced diseases such as castration-resistant disease or hormone-refractory disease. Thats where a lot of the new drugs came in. We started studying the drugs in the [patients with] worse disease because they had a very minimal life expectancy. We were seeing with every one of these drugs like apalutamide and enzalutamide [being being used for] patients who were refractory to everything. Now its moving up to the adjuvant setting and even active surveillance. Whether we see progression or regression of these agents being moved to earlier [lines of therapy], I dont think were too far off from seeing this in the future. Were going to be able to treat patients earlier with triplet therapy like this. Maybe [they will] not continue it for the rest of their lives, but we dont do that with a lot of chemotherapies. Were going to evolve into that, but right now were looking at whats happened with the triplet drugs and celebrating the results. Were going to start moving it up [the lines of therapy].
Go here to see the original:
- Days of our Lives' Suzanne Rogers on the Evolution of Maggie: "She Knows Who She Is Now, and She's Not Relying ... - Michael Fairman TV - March 14th, 2024 [March 14th, 2024]
- Kylie Jenner Talks About Her Style Evolution - The Cut - March 14th, 2024 [March 14th, 2024]
- Equator Coffees Unveils New Packaging Design, Reflecting Brand Evolution & Vision For The Future - Sprudge - March 14th, 2024 [March 14th, 2024]
- Rosewood Hotel Group Accelerates Growth And Evolution Across Its Four Distinctive Brands - Hospitality Net - March 14th, 2024 [March 14th, 2024]
- Thomson Reuters Unveils New Brand Evolution - Adweek - March 14th, 2024 [March 14th, 2024]
- Is It Becoming Acceptable to Speak of Design? - Discovery Institute - March 14th, 2024 [March 14th, 2024]
- Did Charles Darwin Convert to Christianity and Discredit Evolution on His Deathbed? - Snopes.com - March 14th, 2024 [March 14th, 2024]
- Milk, it's not just for mammals: An amphibian makes it too - NPR - March 14th, 2024 [March 14th, 2024]
- Discover Puerto Rico Debuts Evolution of Its Successful 'Live Boricua' Brand Campaign Aimed at Engaging Visitors ... - Yahoo Finance - March 14th, 2024 [March 14th, 2024]
- A Journey Through Time: The Evolution of Ras Al Khaimah Art - Business Wire - March 14th, 2024 [March 14th, 2024]
- Empowering Women: The Evolution and Innovation of coto Social Platform - CXOToday.com - March 14th, 2024 [March 14th, 2024]
- The Evolution of Da'Vine Joy Randolph - The Root - March 14th, 2024 [March 14th, 2024]
- Study on mating behaviors offers clues into the evolution of attraction - Phys.org - March 14th, 2024 [March 14th, 2024]
- Dragonball Evolutions live-action Goku says goodbye to Toriyama: Sorry we messed up - AS USA - March 14th, 2024 [March 14th, 2024]
- Investec, evolution of SMEs in the materials handling sector - Leasing Life - March 14th, 2024 [March 14th, 2024]
- Pride & Prejudice and the evolution of the female gaze on screen - Yahoo News UK - March 6th, 2024 [March 6th, 2024]
- Joe Wong's Musical Evolution - Shepherd Express - March 6th, 2024 [March 6th, 2024]
- A global survey of prokaryotic genomes reveals the eco-evolutionary pressures driving horizontal gene transfer - Nature.com - March 6th, 2024 [March 6th, 2024]
- Redefining Intelligence: Chimpanzees Break Through the Cultural Evolution Barrier - Medriva - March 6th, 2024 [March 6th, 2024]
- Mollusk Eyes Reveal How Future Evolution Depends on the Past - Quanta Magazine - March 6th, 2024 [March 6th, 2024]
- Levy Delves Into the Evolution of ADCs in NSCLC - OncLive - March 6th, 2024 [March 6th, 2024]
- The Snake Is The Spearhead of Reptile Evolution, But Why? - ScienceAlert - March 6th, 2024 [March 6th, 2024]
- 'A very special day: Birds linked to Darwins theory of evolution reintroduced to Galapagos Islands - Euronews - March 6th, 2024 [March 6th, 2024]
- Why the Powerhouses of Cells Evolve Differently in Plants - College of Natural Sciences - March 6th, 2024 [March 6th, 2024]
- Driving the DevOps Evolution: ArgoCD, Tekton and Seamless Migrations - DevOps.com - March 6th, 2024 [March 6th, 2024]
- Finding the Balance: The Evolution of Public Health Guidance Amidst Controversy - Medriva - March 6th, 2024 [March 6th, 2024]
- Insider Podcast: Paolini dishes on her Polish roots and hard-court evolution - WTA Tennis - March 6th, 2024 [March 6th, 2024]
- Interview: Sara Gruen and Rick Elice Talk About the Inspiration and Evolution of the New Musical Water for Elephants - TheaterMania.com - March 6th, 2024 [March 6th, 2024]
- The Evolution of the Laravel Welcome Page - Laravel News - March 6th, 2024 [March 6th, 2024]
- A Serpentine 'Explosion' 125 Million Years Ago Primed Snakes for Rapid, Diverse Evolution - Smithsonian Magazine - March 6th, 2024 [March 6th, 2024]
- The Evolution of Modern Technologies in Car Development - FinSMEs - March 6th, 2024 [March 6th, 2024]
- Milwaukee Transformed: From Bronzeville to Veterans Park, Aerial Timelapses Reveal City's Evolution - BNN Breaking - March 6th, 2024 [March 6th, 2024]
- The eyes are a gateway to evolution of daddy longlegs at least. - University of Wisconsin-Madison - March 6th, 2024 [March 6th, 2024]
- Adrian Newey: RB20 is the next step in Red Bull's design evolution - PlanetSport - March 6th, 2024 [March 6th, 2024]
- LiveScore releases its 'Evolution of Fan' report - Gambling Insider - March 6th, 2024 [March 6th, 2024]
- The loyalty program evolution makes its way to the full-service restaurant category - Nation's Restaurant News - March 6th, 2024 [March 6th, 2024]
- Teenage Mutant Ninja Turtles: The Last Ronin II - Re-Evolution #1 spoiler-free review: goes hard on the action, but ... - Gamesradar - March 6th, 2024 [March 6th, 2024]
- Exploring U.S. Financial Evolution: DAR Hosts Talk on Federal Reserve History in Thomasville - BNN Breaking - March 6th, 2024 [March 6th, 2024]
- Why cloud evolution needs a cohesive approach to succeed - CIO - March 6th, 2024 [March 6th, 2024]
- Gilead Sciences CEO on Company's Evolution and Commitment to the Bay Area - BioSpace - March 6th, 2024 [March 6th, 2024]
- Navigating the AI Quandary: Human Supremacy vs Machine Intelligence Evolution - BNN Breaking - March 6th, 2024 [March 6th, 2024]
- Denis Villeneuve breaks down the evolution of sandworms in 'Dune: Part Two' - Mashable - March 6th, 2024 [March 6th, 2024]
- Continued evolution of law improves governing capacity - Chinadaily.com.cn - China Daily - March 6th, 2024 [March 6th, 2024]
- The Evolution of the DEX Space with dYdX's CEO Antonio Juliano - Blockster - March 6th, 2024 [March 6th, 2024]
- Quick Commerce Evolution: 3PL Firms Aim for Same Day Delivery, Chasing Blinkit and Zepto's Lead - BNN Breaking - March 6th, 2024 [March 6th, 2024]
- What If...? Star Jeffrey Wright Addreses the Watcher's Evolution and 'Epic' Season 2 Finale - CBR - Comic Book Resources - December 31st, 2023 [December 31st, 2023]
- Evolution of the Connected Autonomous Vehicle - Ward's Auto - December 31st, 2023 [December 31st, 2023]
- A project to capture the evolution of human culture. - Psychology Today - December 31st, 2023 [December 31st, 2023]
- The Evolution of a Digital Soul. Beyond Code: A Journey of Heart and | by Mark Randall Havens | Dec, 2023 - Medium - December 31st, 2023 [December 31st, 2023]
- 4 Clues That Reid Is Finally Returning In Criminal Minds: Evolution Season 2 - Screen Rant - December 31st, 2023 [December 31st, 2023]
- Evolution of Samoyed and Kitten's Friendship Delights Internet: 'Wholesome' - Newsweek - December 31st, 2023 [December 31st, 2023]
- Crypto Evolution: Pullix (PLX) vs OKB (OKB) & KuCoin (KCS) - Crypto Reporter - December 31st, 2023 [December 31st, 2023]
- Alfa Romeos mediocre F1 season heralded its era of evolution: Prime Tire - The Athletic - December 31st, 2023 [December 31st, 2023]
- Beyond The Uniform: 10 Years of Evolution in SYNC Performance's Custom Program - SkiRacing.com - December 31st, 2023 [December 31st, 2023]
- Why SZA's evolution into a popstar has earned her recognition as artist of the year - Salon - December 31st, 2023 [December 31st, 2023]
- AI in 2023 Rises, Falls and Evolution - Finance Magnates - December 31st, 2023 [December 31st, 2023]
- Indonesia's Indosat pursues evolution from telecom to tech company - Nikkei Asia - December 31st, 2023 [December 31st, 2023]
- EdTech Evolution: 3 Stocks Educating the Next Generation - InvestorPlace - December 31st, 2023 [December 31st, 2023]
- Informa Tech Interview with Huawei about voice evolution and innovations at 5G Core Summit 2023 - Informa Tech ... - Light Reading - December 31st, 2023 [December 31st, 2023]
- Looking ahead: What will the DeFi evolution look like in 2024? - Ledger Insights - Ledger Insights - December 31st, 2023 [December 31st, 2023]
- Why Cat Bohannon wrote 'Eve, How the Female Body Drove 200 Million Years of Human Evolution' | India News ... - IndiaTimes - December 31st, 2023 [December 31st, 2023]
- The smart-design evolution of the laboratory space - pharmaphorum - December 31st, 2023 [December 31st, 2023]
- The WILD Evolution of Teenage Mutant Ninja Turtles TMNT (VIDEO) - FandomWire - December 31st, 2023 [December 31st, 2023]
- The supernatural invades American museums via indigenous artifacts - Why Evolution Is True - December 31st, 2023 [December 31st, 2023]
- Baleen Whales First Evolved Large Body Size in Cold Southern Waters, New Fossil Shows - Sci.News - December 31st, 2023 [December 31st, 2023]
- The Evolution of Identity in Taiwan The Diplomat - The Diplomat - December 31st, 2023 [December 31st, 2023]
- From the Archive: The Evolution Of Hockey Pools - The Hockey News - December 31st, 2023 [December 31st, 2023]
- 'X-Men: Evolution' Is Better Than 'X-Men: The Animated Series' - Collider - December 31st, 2023 [December 31st, 2023]
- Unveiling the Silver Screen: The Evolution of Celebrity Nudity in Cinema - The Hype Magazine - December 31st, 2023 [December 31st, 2023]
- Are Humans Still Evolving? 'Maybe More Rapidly Than Ever,' Says Scientist - Newsweek - December 31st, 2023 [December 31st, 2023]
- The Intersection of Real Estate and Fintech: Evolution, Impact of Policies, and Global Dynamics - CXOToday.com - December 31st, 2023 [December 31st, 2023]
- Kyle Richards' Style Evolution: Her Best Looks - Us Weekly - December 31st, 2023 [December 31st, 2023]
- Criminal Minds: Evolution Season 2's "Deeper Secrets" Teased By Aisha Tyler - Screen Rant - December 31st, 2023 [December 31st, 2023]
- Saturday: Hili dialogue Why Evolution Is True - Why Evolution Is True - December 31st, 2023 [December 31st, 2023]
- NBA 2K24 MyTEAM New Year Resolution Adds 14 Evolution Cards - ClutchPoints - December 31st, 2023 [December 31st, 2023]
- dive into the history of NASA's logo evolution from the space ... - Designboom - November 8th, 2023 [November 8th, 2023]
- Resolving the puzzle of same-sex sexual interactions - Nature.com - November 8th, 2023 [November 8th, 2023]
- The History and Evolution of Black Friday And How It Got Its Name - Yahoo Life - November 8th, 2023 [November 8th, 2023]
- Evolution of Terran R, with Tim Ellis (Relativity Space) - Payload - November 8th, 2023 [November 8th, 2023]
- Brownell Raves About Breakout Junior's Evolution - The Clemson Insider - November 8th, 2023 [November 8th, 2023]